Pharmicell Asset Resilience Ratio

Latest as of September 2025: 13.89%

Pharmicell asset resilience ratio. Pharmicell (005690) has an Asset Resilience Ratio of 13.89% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Pharmicell to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩18.06 Billion
≈ $12.24 Million USD Cash + Short-term Investments

Total Assets

₩130.02 Billion
≈ $88.12 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio of Pharmicell (2010–2024)

Asset resilience ratio of Pharmicell from 2010 to 2024. This chart shows how Pharmicell's Asset Resilience Ratio has changed over time. Read debt load of Pharmicell for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Pharmicell's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 005690 total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩18.06 Billion 13.89%
Total Liquid Assets ₩18.06 Billion 13.89%

Asset Resilience Insights

  • Moderate Liquidity: Pharmicell has 13.89% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Pharmicell Industry Peers by Asset Resilience Ratio

Compare Pharmicell's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Hyloris Developmentsen Sa
BR:HYL
Biotechnology 1.36%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Biotechnology 53.11%
Gempharmatech Co. Ltd. A
SHG:688046
Biotechnology 23.95%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 74.48%
Inventiva S.A
PA:IVA
Biotechnology 52.73%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%
Guangdong VTR Bio-Tech Co Ltd
SHE:300381
Biotechnology 4.98%

Pharmicell Asset Resilience Ratio by Year (2010–2024)

Pharmicell asset resilience ratio by year from 2010 to 2024. The table below shows the annual Asset Resilience Ratio data for Pharmicell.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.96% ₩2.94 Billion
≈ $1.99 Million
₩99.26 Billion
≈ $67.27 Million
+2.64pp
2023-12-31 0.33% ₩301.28 Million
≈ $204.17K
₩92.52 Billion
≈ $62.70 Million
-10.25pp
2022-12-31 10.58% ₩11.60 Billion
≈ $7.86 Million
₩109.65 Billion
≈ $74.31 Million
-0.05pp
2021-12-31 10.64% ₩10.03 Billion
≈ $6.80 Million
₩94.33 Billion
≈ $63.93 Million
+3.45pp
2020-12-31 7.19% ₩5.01 Billion
≈ $3.40 Million
₩69.74 Billion
≈ $47.26 Million
+3.84pp
2019-12-31 3.35% ₩2.12 Billion
≈ $1.44 Million
₩63.27 Billion
≈ $42.87 Million
-0.14pp
2018-12-31 3.49% ₩2.06 Billion
≈ $1.40 Million
₩59.12 Billion
≈ $40.06 Million
+2.96pp
2017-12-31 0.53% ₩337.72 Million
≈ $228.87K
₩63.75 Billion
≈ $43.20 Million
-6.51pp
2016-12-31 7.04% ₩7.17 Billion
≈ $4.86 Million
₩101.95 Billion
≈ $69.09 Million
+6.15pp
2013-12-31 0.89% ₩880.22 Million
≈ $596.51K
₩99.37 Billion
≈ $67.34 Million
-6.50pp
2012-12-31 7.39% ₩10.08 Billion
≈ $6.83 Million
₩136.43 Billion
≈ $92.45 Million
+1.95pp
2011-12-31 5.43% ₩5.50 Billion
≈ $3.73 Million
₩101.15 Billion
≈ $68.55 Million
+3.55pp
2010-12-31 1.89% ₩560.88 Million
≈ $380.10K
₩29.74 Billion
≈ $20.16 Million
--
pp = percentage points

About Pharmicell

KO:005690 Korea Biotechnology
Market Cap
$361.91 Million
₩534.04 Billion KRW
Market Cap Rank
#13589 Global
#394 in Korea
Share Price
₩8900.00
Change (1 day)
-6.32%
52-Week Range
₩8760.00 - ₩20250.00
All Time High
₩25150.00
About

Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfuse… Read more